Matthew Peterson
Hematology & Oncology · Uvalde, TXNPI 1730475351
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations.
Across 205 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$474
- Novartis$419
- Johnson & Johnson$333
- Bristol Myers Squibb$303
- Incyte Corporation$225
- Gilead$207
- plus $2K from 35 others
Across 20 payments — averaging $6067.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$52K
- Seagen Inc.$30K
- E.r. Squibb & Sons, L.L.C.$22K
- Regeneron$17K
What the payments were for
- Food & beverage$4,18098%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $474 |
| Novartis | 22 | $419 |
| Johnson & Johnson | 11 | $333 |
| Bristol Myers Squibb | 15 | $303 |
| Incyte Corporation | 12 | $225 |
| Gilead | 10 | $207 |
| Karyopharm Therapeutics Inc. | 5 | $187 |
| Bayer | 8 | $185 |
| Sanofi | 8 | $159 |
| Pfizer | 4 | $125 |
| Lilly USA, LLC | 6 | $122 |
| Astellas Pharma US Inc | 5 | $115 |
| E.r. Squibb & Sons, L.L.C. | 5 | $112 |
| Sobi, Inc | 5 | $98 |
| GSK | 5 | $91 |
| Regeneron Healthcare Solutions, Inc. | 3 | $82 |
| Merck | 4 | $78 |
| Eisai Inc. | 3 | $64 |
| AVEO Pharmaceuticals, Inc. | 4 | $64 |
| Array Biopharma Inc | 3 | $64 |
| Geron Corporation | 3 | $64 |
| Daiichi Sankyo Inc. | 3 | $55 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| Recordati_rare_diseases_inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Pharmaand GmbH | 3 | $45 |
| Caris MPI, Inc. | 3 | $44 |
| Pharmacosmos Therapeutics Inc. | 2 | $44 |
| Stemline Therapeutics Inc. | 2 | $43 |
| Puma Biotechnology, Inc. | 2 | $43 |
| Shield Therapeutics Inc | 2 | $37 |
| Blueprint Medicines Corporation | 2 | $36 |
| Tolmar, Inc. | 2 | $32 |
| AbbVie | 2 | $31 |
| Boston Scientific | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Kerecis Limited | 2 | $18 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPOVIO$117
How this compares
$4,279 in reported general payments places this provider in the 55th percentile of 838 hematology & oncology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 36 | $505,145 |
| JakafiRuxolitinib Phosphate | 18 | $330,380 |
| VonjoPacritinib Citrate | 11 | $290,390 |
| SprycelDasatinib | 13 | $212,005 |
| Abiraterone Acetate | 35 | $178,576 |
| IbrancePalbociclib | 11 | $167,460 |
| VerzenioAbemaciclib | 11 | $105,587 |
| EliquisApixaban | 25 | $33,887 |
| OrgovyxRelugolix | 13 | $33,159 |
| XareltoRivaroxaban | 19 | $14,954 |
| Anastrozole | 95 | $1,999 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $1,776 |
| Exemestane | 12 | $1,393 |
| Ondansetron OdtOndansetron | 65 | $892 |
| Fentanyl | 13 | $877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $115 | $505,14536 claims |
| Incyte CorporationJakafi | $225 | $330,38018 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $112 | $212,00513 claims |
| PfizerIbrance, Eliquis | $125 | $201,34636 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $122 | $105,95267 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $29 | $33,15913 claims |
| Johnson & JohnsonXarelto | $333 | $14,95419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Uvalde
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.